All News

Investigators examine the effects of combination therapy with metformin combined with sodium-glucose cotransporter-2 inhibitors, dipeptidyl peptidase-4 inhibitors, or thiazolidinediones.

Mark Garofoli, PharmD, BCGP, CPE, CTTS, also known as “the Pain Guy,” discusses his initial reactions upon learning about the Trump Administration linking acetaminophen use with autism.

Further, after the introduction of the pneumococcal conjugate vaccine 10, investigators note a decrease of infections caused by multidrug resistance infection.

In part 3 of our interview with Rae McMahan, she explores her role at Prescryptive Health and how she’s helping pharmacy stakeholders navigate complex GLP-1 prescription drug benefits.

The model is designed to increase access, utilization, and adherence to insulin by lowering its maximum price.

Pooja Babbrah, executive vice president of strategy and industry alignment at NCPDP, joined Drug Topics to discuss the power of pharmacy standards in helping patients, pharmacists, and more.

Along with the Senior Care Pharmacy Coalition, 3 additional long-term care advocacy groups have joined in on calls to pass the Preserving Patient Access to Long-Term Care Pharmacies Act.

As part of this announcement, the administration launches initiatives across the National Institutes of Health, the FDA, and the Center for Medicare & Medicaid Services.

Through her work as senior vice president of payor solutions at Prescryptive Health, Rae McMahan shares insights into how increased GLP-1 popularity and costs impact pharmacies.

The vote for state and local jurisdictions requiring a prescription for administration of COVID-19 vaccines failed after a tiebreaker vote from the committee chair.

Rae McMahan, senior vice president of payor solutions at Prescryptive Health, discusses GLP-1 access, advertising, and the challenges that often accompany this drug class.

The clinical impact of sodium-glucose cotransporter 2 inhibitors on adults with type 2 diabetes calls for further research on the risk factors of treatment failure and patients’ economic outcomes.

Bumetanide nasal spray is available in 0.5 mg, which is an alternative to traditional oral and intravenous formulations for outpatient therapies.

Dani Markus, PharmD, MBA, discusses the importance of technology in the modern pharmacy era and how it's helping community pharmacists become central figures in health care.

Athena Rae Roesler, MPH, and Anna Lin-Schweitzer, MPH, from the Milken Institute, discuss pharmacists’ role as essential care partners that improve a variety of health concerns for their community’s patients.

Saeed Aboelzahab, director of consumer health at Cardinal Health, discusses the opportunities for community pharmacies to grow revenue through Medicare Advantage OTC benefits.

Shantel Upshaw Houston, PharmD, discusses the vital role of pharmacists in bridging health care gaps and fostering community connections to improve patient care.

Tripp Logan, PharmD, and Jake Galdo, PharmD, discuss the nuances behind community pharmacy practices and the importance of understanding patient, policymaker, and provider perspectives.

Chris Bell, JD, vice president of business operations at API Warehouse, discusses proactive approaches in preventing fraudulent threats and staying compliant with DSCSA.

FDA approves ruxolitinib cream for children with atopic dermatitis, offering a new nonsteroidal treatment option for better symptom management.

This year’s event, from October 18-21, 2025, will take place in New Orleans, Louisiana, at the Ernest N. Morial Convention Center.

The recommendations are provided through the West Coast Health Alliance and pull from guidance from the American Academy of Pediatrics and other organizations.

While experts agree there is no one-size-fits-all approach, addressing medication nonadherence among patients presents opportunities for pharmacists to set themselves apart as medication counselors.

Hyperkalemia, chronic kidney disease, and hypertension often don’t manifest until the diseases become chronically uncontrolled, according to Ralph J. Riello III, PharmD, BCPS.

In an exploration of cardiovascular outcomes, health care utilization, and patient costs, researchers compare glucagon-like peptide-1s with alternative noninsulin glucose-lowering therapies.

This episode explores how recent trends in the retail community pharmacy industry are informing the actions of pharmacy leadership and their teams across the country.

The FDA also grants the biosimilar provisional interchangeability designation, making the drug substitutable at the pharmacy level.

In part 3 of our interview with Andrew Maiorini, PharmD, FAHM, vice president of clinical programs at PerformRx, he discusses the ways in which his company is helping patients stay adherent on their medications.